Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Phase 1 Completed 65 enrolled Robert Wesolowski

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.

Timeline

Start: 2011-06-21
Primary completion: 2022-11-28
Completion: 2022-11-28

Publications

Background Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg M, Ramaswamy B, Fowler J, Wei L, Overholser J, Kaumaya PTP. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. Clin Cancer Res. 2019 Jun 15;25(12):3495-3507. doi: 10.1158/1078-0432.CCR-18-3997. Epub 2019 Feb 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HER-2 vaccine	Vaccine	1 mg	Intramuscular
Subject	HER-2 vaccine	Vaccine	1.5 mg	Intramuscular
Subject	HER-2 vaccine	Vaccine	2 mg	Intramuscular
Subject	HER-2 vaccine	Vaccine	2.5 mg	Intramuscular

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Summary

Timeline

Publications

Drugs

Indications